Pheochromocytoma medical therapy

Pheochromocytoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Pheochromocytoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pheochromocytoma medical therapy On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pheochromocytoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pheochromocytoma medical therapy
CDC on Pheochromocytoma medical therapy
Pheochromocytoma medical therapy in the news
Blogs on Pheochromocytoma medical therapy
Directions to Hospitals Treating Pheochromocytoma
Risk calculators and risk factors for Pheochromocytoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

Any surgical option requires prior treatment with both the non-specific alpha adrenoceptor blocker phenoxybenzamine to counteract hypertension and the beta-1 adrenoceptor antagonist atenolol to reduce cardiac output. Given before surgery, these can also block the effect of a sudden release of adrenaline during tumour removal, which would otherwise endanger the anaethetised patient.